NCT03875638View on ClinicalTrials.gov

Treating Hyperexcitability in AD With Levetiracetam

PHASE2RecruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions
Alzheimer DementiaAlzheimer DiseaseDementia of Alzheimer TypeMild Cognitive Impairment
Interventions
DRUG

Levetiracetam

Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability

DRUG

Placebo oral capsule

The placebo is a capsule that is identical in appearance to the levetiracetam

Trial Locations (1)

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER